BlackRock
IMDX

BlackRock’s Insight Molecular Diagnostics IMDX Stock Holding History

BlackRock’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$444K Buy
135,345
+3,984
+3% +$23.1K ﹤0.01% 4559
2025
Q4 		$985K Buy
131,361
+43,410
+49% +$245K ﹤0.01% 4315
2025
Q3 		$292K Buy
87,951
+1,453
+2% +$4.1K ﹤0.01% 4599
2025
Q2 		$261K Buy
86,498
+6,913
+9% +$20.9K ﹤0.01% 4605
2025
Q1 		$244K Sell
79,585
-372
-0.5% -$1.01K ﹤0.01% 4567
2024
Q4 		$190K Buy
79,957
+124
+0.2% +$337 ﹤0.01% 4629
2024
Q3 		$228K Buy
79,833
+7,006
+10% +$21.7K ﹤0.01% 4502
2024
Q2 		$215K Buy
72,827
+12,640
+21% +$34.7K ﹤0.01% 4537
2024
Q1 		$176K Hold
60,187
– – ﹤0.01% 4617
2023
Q4 		$150K Sell
60,187
-106
-0.2% -$326 ﹤0.01% 4708
2023
Q3 		$188K Sell
60,293
-308
-0.5% -$1.15K ﹤0.01% 4693
2023
Q2 		$279K Sell
60,601
-10,668
-15% -$53.7K ﹤0.01% 4649
2023
Q1 		$505K Buy
71,269
+349
+0.5% +$2.59K ﹤0.01% 4526
2022
Q4 		$455K Sell
70,920
-44,347
-38% -$489K ﹤0.01% 4634
2022
Q3 		$1.68M Sell
115,267
-1,904
-2% -$33K ﹤0.01% 4276
2022
Q2 		$2.11M Sell
117,171
-129,511
-53% -$2.95M ﹤0.01% 4236
2022
Q1 		$7.35M Sell
246,682
-2,975
-1% -$95.1K ﹤0.01% 3750
2021
Q4 		$10.8M Buy
249,657
+31,220
+14% +$1.8M ﹤0.01% 3627
2021
Q3 		$15.6M Sell
218,437
-18,049
-8% -$1.66M ﹤0.01% 3446
2021
Q2 		$27.1M Sell
236,486
-11,925
-5% -$1.16M ﹤0.01% 3116
2021
Q1 		$25.8M Buy
248,411
+73,309
+42% +$6.96M ﹤0.01% 3045
2020
Q4 		$8.37M Buy
175,102
+10,433
+6% +$383K ﹤0.01% 3460
2020
Q3 		$4.58M Buy
164,669
+34,738
+27% +$996K ﹤0.01% 3612
2020
Q2 		$4.96M Buy
129,931
+51,653
+66% +$2.67M ﹤0.01% 3524
2020
Q1 		$3.83M Sell
78,278
-1,072
-1% -$52.6K ﹤0.01% 3452
2019
Q4 		$3.57M Sell
79,350
-53
-0.1% -$1.91K ﹤0.01% 3598
2019
Q3 		$3.33M Buy
79,403
+1,703
+2% +$66.9K ﹤0.01% 3599
2019
Q2 		$3.87M Buy
77,700
+71,415
+1,136% +$5.94M ﹤0.01% 3598
2019
Q1 		$497K Buy
6,285
+2,978
+90% +$192K ﹤0.01% 4103
2018
Q4 		$91K Hold
3,307
– – ﹤0.01% 4372
2018
Q3 		$166K Hold
3,307
– – ﹤0.01% 4360
2018
Q2 		$169K Sell
3,307
-6,952
-68% -$342K ﹤0.01% 4348
2018
Q1 		$431K Sell
10,259
-100
-1% -$6.61K ﹤0.01% 4075
2017
Q4 		$964K Buy
10,359
+861
+9% +$97.1K ﹤0.01% 3907
2017
Q3 		$1.44M Sell
9,498
-387
-4% -$40.5K ﹤0.01% 3796
2017
Q2 		$1.03M Buy
9,885
+5,810
+143% +$661K ﹤0.01% 3845
2017
Q1 		$485K Buy
+4,075
New +$471K ﹤0.01% 3965
2016
Q2 		– Sell
-3
Closed – – 3793
2016
Q1 		$0 Buy
+3
New +$266 ﹤0.01% 3720

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
FOR
Family Office Research Bethesda, Maryland $230M AUM 23.5% 1-Year Est. Return

BlackRock's IMDX Position: Q1 2026 in Review

BlackRock increased its Insight Molecular Diagnostics (IMDX) stake by 3% in Q1 2026, buying an estimated $23.1K and bringing the position to 135,345 shares worth $444K. The position accounts for ﹤0.01% of the portfolio, ranked #4559.

BlackRock first reported a position in IMDX in Q1 2016 and has held it in 38 quarters since. The position peaked at $27.1M in Q2 2021. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • BlackRock held 135,345 shares of Insight Molecular Diagnostics worth $444K as of Q1 2026.
  • BlackRock bought 3,984 Insight Molecular Diagnostics shares in Q1 2026, an estimated $23.1K.
  • Insight Molecular Diagnostics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4559 holding.
  • BlackRock first reported a position in Insight Molecular Diagnostics in Q1 2016 and has held it in 38 quarters since.
  • BlackRock's Insight Molecular Diagnostics position peaked at $27.1M in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.